DailyIQ
Last updated1 minute ago

MRK·Merck & Co., Inc.

$147.36
+5.38 (+3.79%)
High
$148.16
Open
$143.10
Market Cap
357.28B
52W High
$157.00
Low
$142.15
P. Close
$147.36
P/E
112.60
52W Low
$82.00
Fwd P/E
15.24
DailyIQ Est.
$165.49
Inst. Ownership
40.2%
Short Interest
1.13%
Days to Cover
2.5
Div. Yield
2.39%
Next Ex-Div
~Dec 15
Div. Growth
15+ yrs
Technical Score (1D)
91
BULLISH
News Sentiment
37
BEARISH
On Oct 13, Merck closed the trading day at $141.98, lagging the S&P 500. On Oct 13, investors were awaiting the company’s earnings release on Oct 29, 2026, where analysts projected a 17.83% decline in earnings per share and a slight revenue drop. On Oct 13, the market reaction reflected concerns about weaker quarterly results and potential impact on future guidance. On Oct 13, the pharmaceutical company’s stock had underperformed the medical sector and the broader market over the past month. On Oct 13, the company was expected to report a decline in EPS for the upcoming quarter. On Oct 13, investors were monitoring the earnings release for potential guidance adjustments.
LOW TARGET
$105 -28.8%
2 analysts
MEAN TARGET
$159 +7.7%
22 analysts
HIGH TARGET
$186 +26.2%
14 analysts
PRICE RANGE
$105.00 - $186.00
SB / B / H / S / SS
8/18/10/1/1
DAILYIQ EST.
$165.49 (+12.3%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
Symbol
MRK
Description
Merck & Co., Inc. is a global healthcare leader focused on discovering, developing, and delivering innovative medicines and vaccines. The company's core business centers on human health pharmaceuticals, with a diverse portfolio of treatments spanning various therapeutic areas, including oncology, vaccines, and diabetes. Merck also maintains a significant presence in animal health, providing veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Strategic collaborations with other pharmaceutical companies support its research and development efforts, expanding its pipeline of potential treatments. Founded in 1891, Merck's operations are headquartered in Rahway, New Jersey.
Bought (1Y)
0 shares
$0
Sold (1Y)
218,238 shares
$28.6M
Coe Mary Ellen-
Award/Grant206.455 shares2026-09-30
Karsanbhai Surendralal Lanca-
Award/Grant111.83 shares2026-09-30
Seidman Christine E-
Award/Grant55.915 shares2026-09-30
Zachary JenniferEVP, General Counsel
Option Exercise13,433 shares2026-08-12
Zachary JenniferEVP, General Counsel
Option Exercise41,494 shares2026-08-12
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
28.1%
Revenue CAGR
5.6%
Current Ratio
1.54x
Debt / Equity
0.93x
Return on Equity
34.7%
Earnings Summary
Merck & Co., Inc. is a global healthcare leader focused on discovering, developing, and delivering innovative medicines and vaccines, with a core portfolio spanning oncology, vaccines, diabetes, and animal health. In the last two quarters, Merck’s EPS grew from $2.13 in Q1 2025 to $2.58 in Q3 2025, while revenue climbed from $15.53 billion to $17.28 billion, reflecting a 10.4% YoY increase in earnings and a 11.1% YoY rise in sales; the company consistently beat estimates in each of the last four quarters, with EPS exceeding forecasts by 3.3% to 12.5% and revenue surpassing expectations by 1.2% to 2.8%. Historically, Merck has maintained a steady upward trajectory, with EPS growth of 8.5% in Q4 2024 and 9.7% in Q1 2025, and revenue growth of 6.3% and 7.1% respectively; the firm has repeatedly outperformed analyst estimates, underscoring a pattern of robust earnings performance even when revenue growth moderates. Recent news highlights a 38% share price surge in 2026 following a revised mid‑2030s sales opportunity of over $70 billion, and a Dutch court block of Keytruda SC in eight countries, illustrating the impact of regulatory developments on investor sentiment. Forward‑looking watch points for investors include monitoring the upcoming Q1 2026 earnings for a potential EPS decline, as analysts anticipate a 17.83% year‑over‑year drop, and assessing how the company’s guidance adjustments may influence future revenue projections.

EPS

EstBeatMiss
$-1.86$-0.60$0.65$1.90$3.16Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.10 - -
Q2'26$-0.27$-0.13+52.4%
Q1'26$2.09$-1.28-161.2%
Q4'25$2.03$2.04+0.5%
Q3'25$2.35$2.58+9.9%
Q2'25$2.03$2.13+5.0%

Revenue

EstBeatMiss
$15.6B$16.1B$16.6B$17.2B$17.7BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$17.5B - -
Q2'26$16.5B$16.6B+0.5%
Q1'26$16.2B$16.3B+0.7%
Q4'25$16.3B$16.4B+0.3%
Q3'25 - $17.3B -
Q2'25 - $15.8B -

Market Data

MRK Stock Snapshot

BULLISH91/100
$147.36+$5.38 (3.8%)
Market cap
357.28B
P/E ratio
112.6
Day range
$142.15 – $148.16
News sentiment
37/100 · Bearish
Analyst target
$158.64 (+7.7%)
Consensus
Buy · 38 analysts
52-week range+79.7% off low · -6.1% from high
$82.00$157.00
Price $147.36 DailyIQ Est. $165.49

Price is in the upper part of its 52-week range, and the momentum read backs that positioning up. Coverage is deep enough that new information gets priced quickly, so surprises tend to be macro rather than fundamental.

Reverse DCF

What growth is priced into MRK?

RICH

At today's price, Merck & Co., Inc. needs to grow free cash flow about 11.8% a year for the next 10 years to justify its valuation at a 7.36% cost of capital. Over its actual history it has compounded free cash flow at 4.9% a year, so the market is asking for 6.9 percentage points above its own delivered rate. On that basis MRK looks priced above what its own growth record supports.

Implied FCF growth
11.8%
Historical FCF CAGR
4.9%
Growth gap
+6.9 pts
Verdict
RICH
Discount rate (WACC)
7.36%
Beta
0.56

Behaviour On Record

What MRK's own history says about today's numbers

Realized volatility (21d)
24.3% 78th pct
Below its peak
-9.4%
vs 200-day average
+14.4%
Up days (1y)
55%

Merck & Co., Inc. is currently running 24.3% annualised volatility over the last 21 sessions. Measured against MRK's own 13 years of daily returns rather than a market-wide average, that is the 78th percentile — elevated for this stock, against a typical reading of 19.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

MRK is trading -9.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.3%, and the deepest was -27.8% in 2024. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +14.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 86th percentile — a wider gap than this stock usually carries. Over the past year MRK closed higher on 55% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 13 years of records, MRK finished the month higher 6 of 13 times, with a median return of -1.4% and an average of -0.8%. Its strongest month historically has been November at +4.1% on average, its weakest September at -1.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: MRK has opened more than 2% away from the prior close in 30 of 3,267 sessions (0.9% of the time), with the largest gaps running +5.3% and -4.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, MRK moved an average of 0.8% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.8% and a largest of +1.1%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against MRK's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of MRK's sector?

Merck & Co., Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for MRK?

CallsPuts

For Merck & Co., Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.35), with at-the-money implied volatility around 32.6%. The options market is pricing roughly a ±2.3% move by that expiry — a range of about $143.81–$150.53.

Put/call ratio (2026-10-16)
0.35
ATM implied volatility
32.6%
Total open interest
70,218
Expected move by 2026-10-16
±2.3% ($143.81–$150.53)

Analyst Rating Changes

Are analysts turning bullish or bearish on MRK?

Citigroup most recently reiterated its rating on Merck & Co., Inc. to Neutral on Oct 12, 2026 with a price target of $145 (from $125). Over the last 90 days, coverage has run 2 upgrades against 1 downgrade, a net bullish lean.

Latest action
Citigroup — Neutral
90-day upgrades
2
90-day downgrades
1
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 12, 2026CitigroupMaintainedNeutral$125 → $145
Oct 12, 2026RBC CapitalMaintainedSector Perform$150 → $145
Oct 8, 2026Cantor FitzgeraldMaintainedNeutral$120 → $145
Oct 7, 2026Morgan StanleyMaintainedOverweight$179 → $177
Oct 5, 2026JP MorganMaintainedOverweight$150 → $165
Sep 29, 2026ScotiabankMaintainedSector Outperform$155 → $180
Sep 10, 2026HSBCMaintainedBuy$150 → $172
Sep 9, 2026Leerink PartnersMaintainedOutperform$127 → $161
Sep 8, 2026GuggenheimMaintainedBuy$146 → $170
Sep 4, 2026Wells FargoMaintainedOverweight$150 → $170
Aug 25, 2026Wolfe ResearchMaintainedOutperform$155 → $180
Aug 25, 2026Argus ResearchMaintainedBuy$145 → $170

Peers & ETF holders

MRK peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

37/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Merck (MRK) closed the trading day at $141.98, down 2.39% and lagging the S&P 500. The pharmaceutical company’s stock has underperformed the medical sector and the broader market over the past month. Investors are awaiting the company’s earnings release on October 29, 2026, where analysts project a 17.83% decline in earnings per share and a slight revenue drop. The market’s reaction reflects concerns about weaker quarterly results and potential impact on future guidance.
What did this article say?
Merck’s Keytruda, combined with BioNTech’s experimental mRNA therapy, failed to significantly delay disease progression in a late‑stage head and neck cancer trial. The Phase 2/3 Ahead‑Merit study showed no improvement in progression‑free survival compared with Keytruda alone, although overall survival was still being evaluated. The negative result may dampen enthusiasm for the combination and could influence future development plans for Merck’s oncology portfolio.
What did this article say?
Merck’s shares climbed 38% in 2026 after the company announced a significant upward revision of its non‑risk‑adjusted sales opportunity to more than $70 billion by the mid‑2030s. CEO Robert Davis highlighted the upside at a Morgan Stanley conference, emphasizing new multibillion‑dollar assets outside the $70 billion figure. The company also faced a setback when a Dutch court blocked the Keytruda SC version in eight countries, but the overall outlook remains strongly positive. Investors are now anticipating further guidance and Q3 results to confirm the upside.
What did this article say?
Merck presented one-year data from its Phase 2b/3 BRUNELLO study on remigromig, a novel tri‑specific antibody targeting the Wnt pathway, at the AAO 2026 meeting. The investigational drug achieved non‑inferiority in mean change from baseline in best‑corrected visual acuity compared with ranibizumab, a standard anti‑VEGF therapy. The results suggest remigromig could offer an alternative treatment for diabetic macular edema, potentially addressing the unmet need of patients who remain refractory to existing therapies.
What did this article say?
Merck’s stock, trading near $145.60, faces scrutiny as its 117% five‑year gain is weighed against upcoming patent expiries and significant capital outlays. Analysts highlight the 2028 expiry of Keytruda, which could erode future cash flows, and note that new oncology deals and trial results will influence the timing of pipeline monetization. The company’s high P/E ratio of 113.2x and a discounted cash flow estimate suggest the current price may be overvalued relative to projected earnings. Investors are cautioned to assess whether Merck’s valuation aligns with realistic cash‑generation prospects.
What did this article say?
Merck’s shares rose by 3% on Oct 9 as part of a broader biotech rally that also saw Novavax and Moderna climb. The increase was largely driven by sector momentum rather than any company‑specific news or guidance. No new product announcements or guidance updates were reported. The move reflects positive market sentiment but does not signal a material shift in Merck’s fundamentals.
What did this article say?
BofA Securities reduced its price target for Merck & Co. from $166 to $163 while keeping a buy recommendation. The adjustment reflects a modest reassessment of the company’s valuation, but the overall stance remains positive. The change is unlikely to materially alter market expectations or investor sentiment.

Technical Analysis

Real-time indicators across multiple timeframes

91
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $123.10B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy226,999,8379.03%$29.17B2026-08-07
Vanguard Group Inc▲ Buy254,322,76310.12%$26.77B2026-01-29
Wellington Management Group LLP▲ Buy86,249,2833.43%$11.08B2026-08-14
Geode Capital Management, LLC▲ Buy60,744,2142.42%$7.79B2026-08-12
Morgan Stanley▲ Buy48,641,1581.94%$6.25B2026-08-13
FMR LLC (Fidelity)▲ Buy45,440,3551.81%$5.84B2026-08-13
JPMorgan Chase & Co▼ Sell43,886,4201.75%$5.68B2026-08-12
Fisher Asset Management, LLC▲ Buy38,516,2631.53%$4.95B2026-08-04
Norges Bank▼ Sell36,983,7841.47%$4.75B2026-08-12
Bank of America Corp▼ Sell30,535,2081.22%$3.92B2026-08-14
Northern Trust Corp▼ Sell26,275,7181.05%$3.38B2026-08-13
Goldman Sachs Group Inc▲ Buy22,075,1390.88%$2.84B2026-08-14
Invesco Ltd.▼ Sell18,611,1710.74%$2.39B2026-08-14
AllianceBernstein L.P.▲ Buy13,131,9420.52%$1.58B2026-08-14
Harris Associates L P▼ Sell12,073,1090.48%$1.55B2026-08-14
Wells Fargo & Company▲ Buy11,658,4340.46%$1.50B2026-08-14
AQR Capital Management LLC▼ Sell8,134,2620.32%$1.04B2026-08-14
Citigroup Inc▲ Buy3,614,9050.14%$464.52M2026-08-03
Neuberger Berman Group LLC▲ Buy3,533,9550.14%$454.22M2026-08-13
D. E. Shaw & Co., Inc.▼ Sell2,738,0230.11%$351.84M2026-08-14
Janus Henderson Group plc▲ Buy2,880,1990.11%$346.47M2026-05-18
Adage Capital Partners GP, L.L.C.▼ Sell2,030,0230.08%$260.86M2026-08-14
Citadel Advisors LLC▼ Sell1,933,6670.08%$248.48M2026-09-02
Capital Research Global Investors▼ Sell1,925,0130.08%$247.36M2026-08-12
Prudential Financial Inc▼ Sell1,913,5360.08%$245.89M2026-08-12
Q2 2026 flow:23.38M sh bought ($2.99B)18.56M sh sold ($2.39B)net +4.82M sh (+$596.00M)
Congressional Trading Activity
25 disclosed trades · ~$581.0K est. traded value · 12 buys, 13 sells
MemberChamberStateTypeAmountTradedFiled
Maria Elvira SalazarHouseFL27▼ Sell$1K - $15K2026-09-242026-10-07
Maria Elvira SalazarHouseFL27▲ Buy$15K - $50K2026-08-192026-09-09
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2026-02-042026-03-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Donald J. TrumpSenate-▲ Buy$100K - $250K2025-10-312025-12-19
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-08-282025-08-29
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-05-302025-06-06
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-04-292025-05-06
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-04-082025-05-08
Gilbert CisnerosHouseCA31▼ Sell$15K - $50K2025-03-312025-04-07
Kelly Louise MorrisonHouseMN03▼ Sell$1K - $15K2025-03-202025-04-11
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-032025-04-16
Gilbert CisnerosHouseCA31▲ Buy$15K - $50K2025-02-262025-03-06
Josh GottheimerHouseNJ05▼ Sell$15K - $50K2025-01-272025-02-10
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-01-242025-02-11
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-172025-02-12
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-01-162025-02-10
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2025-01-152025-02-10
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-10-162023-11-16
Pete RickettsSenateNE▼ Sell$50K - $100K2023-09-212023-10-20
Tommy TubervilleSenateAL▲ Buy$1K - $15K2022-03-302022-04-08